Directorio

This study is a big test to see if a new medicine works. It is called a Phase 3 trial. People in the study will be put into groups by chance. One group will get a fake medicine called a placebo, and the other group will get the real medicine. The real medicine is named Seralutinib. It is breathed in two times every day. The study will last for 30 weeks. After that, people can keep taking part for up to two more years. During the study, doctors will do tests like blood draws, heart checks, breathing tests, and pictures of the chest. They will also check how far you can walk in six minutes. There will be 11 visits in the first 30 weeks.

This study is for people with a kind of brain cancer called GBM. They will be placed into one of two treatment groups—either a regular treatment or a new one being tested. The study has two parts. In the first part, doctors choose treatments based on how well they are working for others with similar cancer. In the second part, treatments that look helpful are tested more closely. People in the study will have brain scans every 6 to 8 weeks to check the size of the tumor. They will also have blood tests, physical check-ups, and answer questions about how they feel. Some people may take tests to check their thinking and memory. Treatment will continue until the cancer gets worse or the side effects become too strong. Regular treatments include radiation and a medicine called temozolomide for people who are newly diagnosed. For people whose cancer has come back, the treatment is a chemotherapy medicine called lomustine.

We are doing this study to find the most effective, safe dose of an experimental drug called CTL-002 (the study drug) when it is given in combination with nivolumab and docetaxel for patients who have metastatic non-squamous non-small cell lung cancer (NSCLC).

We are doing this study to understand more about biomarkers (a part of your body) and how they can be used to better diagnose infection. To learn more, please contact us at DukeMESSIStudy@Duke.edu or at 919-452-1605. Estamos haciendo este estudio para entender más sobre biomarcadores (que son parte de su cuerpo) y cómo pueden ser usados estos para diagnosticar infecciones de una mejor manera. Para mayor información, por favor contáctenos al correo DukeMESSIStudy@Duke.edu o al número 919-452-1605.

We are doing this study to learn more about the cause of cardiac (heart) disease or sudden unexplained death, which is something that can run in families. Some conditions that we are looking at are:

• Cardiomyopathies (a disease of the heart muscle that makes it harder for your heart to pump blood to the rest of your body) like hypertrophic cardiomyopathy, dilated cardiomyopathy, or arrhythmogenic cardiomyopathy (also called right ventricular cardiomyopathy)
• Arrhythmia syndromes (a problem with the rate or rhythm of the heartbeat, either too slow or too fast) like long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, or short QT syndrome
• Sudden cardiac arrest or unexplained sudden death (heart stops suddenly) in someone less than 50 years of age, including sudden infant death syndrome (SIDS)
• Individuals with genetic mutations (variants) in genes that can lead to cardiac disease which include (LMNA, ATP1A3, and TAX1BP3)

We are doing this study to learn more about how genetic variations in people can impact how well different antibody-based drugs work for people who get organ transplants.

We are doing this study to find out if an experimental drug called acasunlimab (the study drug) is a safe and effective option for adults with relapsed/refractory, unresectable, locally advanced, or metastatic cutaneous melanoma that has progressed despite treatment with a checkpoint inhibitor. We want to know how well the study drug works on its own and in combination with pembrolizimab.

We are doing this study to learn from patients' experiences about managing gastroesophageal reflux (GERD) and other risks related to lung transplantation.